Primary and secondary metastatic dissemination: multiple routes to cancer-related death

Abstract Metastatic disease accounts for approximately 80% of cancer-related deaths, typically manifesting as single-organ failure mainly through abdominal, cardiovascular, neurological, or respiratory complications. Despite treating thousands of cancer patients daily worldwide, our understanding of...

Full description

Saved in:
Bibliographic Details
Main Authors: D. Sparrer, R. Blazquez, F. Keil, S. Einhell, F. Lüke, S. Uderhardt, C. Gerner, C.H.R. Wendl, M. Proescholdt, C. Schulz, A. Kandulski, S. Haferkamp, H.J. Schlitt, T. Bäuerle, K. Franze, R. Mayr, M. Rechenmacher, P. Hau, D. Hirsch, D. Heudobler, K. Evert, T. Pukrop
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Molecular Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12943-025-02389-5
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Metastatic disease accounts for approximately 80% of cancer-related deaths, typically manifesting as single-organ failure mainly through abdominal, cardiovascular, neurological, or respiratory complications. Despite treating thousands of cancer patients daily worldwide, our understanding of organ-specific metastatic dissemination routes, tissue destruction mechanisms and reasons for organ failures remains limited. As cancer-directed therapies advance, maintaining organ function has emerged as a critical therapeutic goal of care. To develop more effective treatment strategies, a comprehensive understanding of the pathophysiology is essential, particularly regarding secondary and subsequent metastatic waves that lead to extensive macro-metastases and organ failure. Critical distinction between primary metastatic spread and secondary intra-organ dissemination is crucial. In the era of precision oncology, elucidating organ-specific destruction processes and the pathophysiology of metastatic waves is fundamental for advancing patient care. To highlight the emerging goal of care of maintaining organ function, we aligned the metastatic biology, clinical stages, goals of care and therapeutic indications: the Bio Therapeutic Goals of Cancer Care Model.
ISSN:1476-4598